Semaglutide vs SLU-PP-332
A side-by-side research comparison of Semaglutide and SLU-PP-332 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Semaglutide | SLU-PP-332 |
|---|---|---|
| Full name | Semaglutide (GLP-1 Receptor Agonist) | SLU-PP-332 (ERR Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Research compound (preclinical) |
| Mechanism | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. | A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise. |
| Molecular weight | 4,114 Da | ~426 Da (small molecule, not a peptide) |
| Half-life | 7 days (168 hours) | Not well characterized in humans |
| Bioavailability | High (SubQ ~89%), Moderate (oral ~1% with SNAC) | Studied via injection in animals; oral activity under investigation |
| Typical dose | 0.25 mg → titrate up to 2.4 mg | No established human dose |
| Frequency | Once weekly | Unknown |
| Route | Subcutaneous injection | Injection (preclinical) |
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
SLU-PP-332 reported benefits
- Increases mitochondrial fat-burning (preclinical)
- Improved endurance in animals
- Reduced fat gain without appetite change (animals)
- Acts as an "exercise mimetic"
Related comparisons
Research and educational reference only. Not medical advice.